Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Marker Therapeutics stock
Learn how to easily invest in Marker Therapeutics stock.
Marker Therapeutics Inc is a biotechnology business based in the US. Marker Therapeutics shares (MRKR) are listed on the NASDAQ and all prices are listed in US Dollars. Marker Therapeutics employs 44 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Marker Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – MRKR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Marker Therapeutics stock price (NASDAQ: MRKR)Use our graph to track the performance of MRKR stocks over time.
Marker Therapeutics shares at a glance
|Latest market close||$0.81|
|52-week range||$0.83 - $3.77|
|50-day moving average||$1.19|
|200-day moving average||$1.98|
|Wall St. target price||$6.38|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.60|
Buy Marker Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Marker Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Marker Therapeutics price performance over time
|1 week (2022-01-11)||-4.71%|
|1 month (2021-12-16)||-19.00%|
|3 months (2021-10-18)||-48.41%|
|6 months (2021-07-16)||-63.68%|
|1 year (2021-01-15)||-60.87%|
|2 years (2020-01-17)||-74.69%|
|3 years (2019-01-18)||6|
|5 years (2017-01-18)||4.4703|
Marker Therapeutics financials
|Gross profit TTM||$-18,413,966|
|Return on assets TTM||-39.65%|
|Return on equity TTM||-98.03%|
|Market capitalisation||$69.8 million|
TTM: trailing 12 months
Marker Therapeutics share dividends
We're not expecting Marker Therapeutics to pay a dividend over the next 12 months.
Have Marker Therapeutics's shares ever split?
Marker Therapeutics's shares were split on a 1:12 basis on 15 September 2016. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Marker Therapeutics shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Marker Therapeutics shares which in turn could have impacted Marker Therapeutics's share price.
Marker Therapeutics share price volatility
Over the last 12 months, Marker Therapeutics's shares have ranged in value from as little as $0.83 up to $3.77. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Marker Therapeutics's is 1.1424. This would suggest that Marker Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Marker Therapeutics overview
Marker Therapeutics, Inc. , a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial for the treatment of breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Marker Therapeutics in the news
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda
Marker Therapeutics Inc Shares Fall 0.3% Below Previous 52-Week Low - Market Mover
Frequently asked questionsWhat percentage of Marker Therapeutics is owned by insiders or institutions?
Currently 19.941% of Marker Therapeutics shares are held by insiders and 33.97% by institutions. How many people work for Marker Therapeutics?
Latest data suggests 44 work at Marker Therapeutics. When does the fiscal year end for Marker Therapeutics?
Marker Therapeutics's fiscal year ends in December. Where is Marker Therapeutics based?
Marker Therapeutics's address is: Phoenix Tower, Houston, TX, United States, 77027 What is Marker Therapeutics's ISIN number?
Marker Therapeutics's international securities identification number is: US57055L1070 What is Marker Therapeutics's CUSIP number?
Marker Therapeutics's Committee on Uniform Securities Identification Procedures number is: 57055L107
More guides on Finder
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Can Turo’s IPO do better than Uber and Airbnb?
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
Ask an Expert